HALON-hysterectomy by transabdominal laparoscopy or natural orifice transluminal endoscopic surgery : a randomised controlled trial (study protocol) by Baekelandt, Jan et al.
HALON—hysterectomy by
transabdominal laparoscopy or natural
orifice transluminal endoscopic surgery:
a randomised controlled trial (study
protocol)
Jan Baekelandt,1 Peter A De Mulder,2 Ilse Le Roy,2 Chantal Mathieu,3
Annouschka Laenen,4 Paul Enzlin,5 Steven Weyers,6 Ben WJ Mol,7
Jan JA Bosteels1,8
To cite: Baekelandt J,
De Mulder PA, Le Roy I,
et al. HALON—hysterectomy
by transabdominal
laparoscopy or natural orifice
transluminal endoscopic
surgery: a randomised
controlled trial (study
protocol). BMJ Open 2016;6:
e011546. doi:10.1136/
bmjopen-2016-011546
▸ Prepublication history and
additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/bmjopen-2016-
011546).
Received 18 February 2016
Revised 3 May 2016
Accepted 1 June 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Jan J A Bosteels;
Jan.bosteels@hotmail.com
ABSTRACT
Introduction: Natural orifice transluminal endoscopic
surgery (NOTES) uses natural body orifices to access
the cavities of the human body to perform surgery.
NOTES limits the magnitude of surgical trauma
and has the potential to reduce postoperative pain.
This is the first randomised study in women bound
to undergo hysterectomy for benign gynaecological
disease comparing NOTES with classical laparoscopy.
Methods and analysis: All women aged 18–
70 years, regardless of parity, consulting at our
practice with an indication for hysterectomy due to
benign gynaecological disease will be eligible. After
stratification according to uterine size on clinical
examination, participants will be randomised to be
treated by laparoscopy or by transvaginal NOTES.
Participants will be evaluated on day 0, days 1–7 and
at 3 and 6 months. The following data will be
collected: the proportion of women successfully
treated by removing the uterus by the intended
approach as randomised; the proportion of women
admitted to the inpatient hospital; postoperative pain
scores measured twice daily by the women from day
1 to 7; the total amount of analgesics used from day
1 to 7; readmission during the first 6 weeks; presence
and intensity of dyspareunia and sexual well-being at
baseline, 3 and 6 months (Short Sexual Functioning
Scale (SSFS) scale); duration of surgery; postoperative
infection or other surgical complications; direct and
indirect costs incurred up to 6 weeks following
surgery. The primary outcome will be the proportion
of women successfully treated by the intended
technique; all other outcomes are secondary.
Ethics and dissemination: The study was
approved on 1 December 2015 by the Ethics
Committee of the Imelda Hospital, Bonheiden,
Belgium. The first patient was randomised on 17
December 2015. The last participant randomised
should be treated before 30 November 2017. The
results will be presented in peer-reviewed journals
and at scientific meetings within 4 years after starting
recruitment.
Trial registration number: NCT02631837;
Pre-results.
INTRODUCTION
Background
The evolution from traditional open surgery
to laparoscopic surgery has led to a reduc-
tion in surgical morbidity and mortality.
Minimally invasive surgical techniques have
progressed since the introduction of single-
incision laparoscopic surgery (SILS) and
natural orifice transluminal endoscopic
surgery (NOTES), and are often facilitated
by robot assistance.
NOTES is a technique using the natural
orifices (mouth, vagina, urethra and rectum)
as an access route to the peritoneal cavity for
endoscopic surgery. It was described for the
first time in 2004 in a porcine model by
researchers at Johns Hopkins University.1
The clinical application of NOTES has been
reported in general surgical procedures,
such as transgastric appendectomy2 and
cholecystectomy,3 and demonstrated reduced
pain, a shorter length of hospital stay and
less complications. Improved cosmetic results
due to scar-free surgery in combination with
Strengths and limitations of this study
▪ Randomised controlled trial.
▪ Blinding of personnel, participants and outcome
assessors.
▪ Relevant patient-reported outcomes.
▪ Single-centre study.
▪ Limited generalisability.
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reduced wound (trocar) complications, supports the
increasing use of this new surgical technique.
NOTES has gained popularity among general sur-
geons, urologists and gastroenterologists over the past
few years and its feasibility and safety have been
reported.4 It can be performed via various entry
approaches including the stomach, oesophagus, bladder
and rectum. The vast majority of NOTES procedures in
women have been performed through the vagina as this
allows direct access to the peritoneal cavity.5 Culdotomy
has been used widely for several surgical procedures
involving extraction of large specimens: it has been
reported as a safe access that is easy to close afterwards.6 7
In hybrid NOTES the surgical procedure is performed
through a natural body orifice with transabdominal assist-
ance, whereas the term pure NOTES refers to procedures
that involve only transluminal access.
Hysterectomy using a transvaginal NOTES (vNOTES)
approach was described for the first time in a human
patient by Su et al8 in 2012.
Objectives and hypotheses
We conducted a systematic review (SR) of the literature
by searching MEDLINE, EMBASE and the Cochrane
Library from inception to 25 August 2015 using ‘Natural
Orifice Endoscopic Surgery’ and ‘hysterectomy’ as Medical
Subject Headings (MeSH) terms or key words. The
results of this SR will be published in 2016; we will
adhere to the PRISMA-P guidelines9 for writing the
protocol of this SR. The protocol has been registered in
PROSPERO, the international prospective register of
SRs, at the Centre for Reviews and Dissemination
(CRD), University of York, UK,10 with the protocol
number CRD42016033023. To the best of our knowl-
edge no randomised controlled studies comparing
NOTES with the classical laparoscopic approach for hys-
terectomy have been reported in the literature: this is
the main objective of the hysterectomy by transabdom-
inal laparoscopy or NOTES (HALON) study. A rando-
mised controlled trial (RCT) is a study design that has
the advantage to control for all possible known and
unknown confounding variables due to the random
sequence generation as opposed to observational studies
where confounding and bias may be more problematic.
High-quality RCTs are generally considered as being the
gold standard design for the study of the effectiveness of
interventions. The rationale and the objectives of this
trial are in accordance with the guidelines of the IDEAL
collaboration.11–13
The study hypothesis states that hysterectomy by
vNOTES may be at least as effective for removing a non-
prolapsed uterus without the need for conversion to an
alternative technique compared with the classical laparo-
scopic approach. A conversion means the use of any
other technique than the one allocated by random
sequence generation. The following example illustrates a
conversion: a study entrant may be allocated to the
NOTES group but due to technical problems or a
complication the surgeon decides to switch to laparo-
scopic, abdominal or vaginal hysterectomy in the interest
of the patient. vNOTES may offer several advantages
compared with laparoscopy: the avoidance of abdominal
scars, more women leaving the day care unit on the day
of the intervention and less postoperative pain in the
first 7 days following surgery.
METHODS
Trial design and study analysis
This single-centre study is a parallel group RCT conducted
at the Department of Gynaecology of the Imelda Hospital
in Bonheiden, a general hospital in Belgium serving an
estimated population of 150 000 people. A cohort of
women aged 18–70 years with a non-prolapsed uterus
bound to undergo hysterectomy for benign gynaecological
disease will be invited to participate in the study, if eligible.
Prior to randomisation, all eligible women will be stratified
based on the uterine size on clinical examination: category
A=uterine size smaller than 10 weeks of pregnancy, cat-
egory B=uterine size between 10 and 16 weeks of preg-
nancy, and category C=uterine size larger than 16 weeks of
pregnancy. We considered the size of the uterus to be the
most important determinant to affect the primary
outcome (successful removal of the uterus). The surgery
will be performed by one surgeon ( JB) who is equally
skilled in operating with both techniques: he has intro-
duced and refined the NOTES approach since November
2013. Our group published three small case series on
adnexal removal (N=20),14 salpingectomy (N=5)15 and
hysterectomy (N=10)16 performed between November
2013 and February 2015. A non-inferiority study design
will be used. The protocol adheres to the SPIRIT standards
(http://www.spirit-statement.org/) as documented by the
SPIRIT checklist that was sent to BMJ Open Editorial
Office.
Participants
The HALON trial will recruit eligible women aged 18–70
years, regardless of parity, with a non-prolapsed uterus in
need of a hysterectomy for benign indication and who
provide informed consent prior to surgery. There is no
cut-off for the uterine size to exclude women from par-
ticipating in the HALON study. Concomitant unilateral or
bilateral salpingo-oophorectomy when needed is not an
exclusion criterion per se: in our observational personal
experience, adnexal masses up to 20 cm diameter can be
removed without spilling.14 Women will be excluded from
participation if they present any of the following condi-
tions: history of rectal surgery, suspected rectovaginal
endometriosis or malignancy, history of pelvic inflamma-
tory disease, active lower genital tract infection, virginity,
pregnancy or failure to provide written informed consent.
Intervention, procedures and standard care
Women in both groups will be admitted to the day care
unit on the day of hysterectomy. Clindamycin vaginal
cream will be administered on admission.
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In the operating theatre, the patient will be placed in
the lithotomy position in a vacuum mattress. The
abdomen, vulva and vagina will be disinfected with an
alcoholic Betadine solution and draped. A Foley cath-
eter will be inserted into the bladder. Cefazolin 2 g and
metronidazole 1.5 g will be administered intravenously
during the procedure in both groups.
Control group: laparoscopic approach
When randomised to the laparoscopic approach a
reusable Hohl uterus manipulator will be inserted
through the vagina. A small vertical intraumbilical skin
incision will be made. A Veress needle will be inserted
into the peritoneal cavity; the correct position of the
needle tip will be checked with the Semm test. CO2 will
be insufflated until a maximal intraperitoneal pressure
of 15 mm Hg. The Veress needle will then be removed
and replaced by a 10 mm reusable trocar. An optic fibre
will be inserted through the 10 mm trocar and the peri-
toneal cavity will be inspected. The woman will be
placed in the Trendelenburg position. Three reusable
5 mm trocars will be inserted under direct vision in the
left and right iliac fossa lateral of the epigastric vessels,
and in the suprapubic region. The small intestine will be
gently lifted out of the pelvis using atraumatic forceps.
The ureter will be identified, but not routinely dissected
unless indicated. The mesosalpinx will be coagulated
from lateral to medial using a reusable bipolar grasping
forceps and cut using cold scissors. The ovaries will be
left untouched or removed based on the absence or
presence of pathology as counselled to the patient. The
round ligament will be coagulated using a bipolar
grasper and cut using cold scissors. The parametria will
be opened and the bladder will be dissected from the
cervix and cranial part of the vagina. The uterine artery
will be coagulated using a bipolar grasper and cut using
cold scissors. The same procedure will be repeated on
the contralateral side. The vagina will be opened over
the cup of the Hohl manipulator using a reusable mono-
polar hook. The cervix will be excised in a circular
fashion using the vaginal cup of the retractor as a back-
stop. The uterus will be extracted through the vagina.
Haemostasis will be performed using a bipolar grasper.
The vaginal vault will be closed laparoscopically using
three figure of eight vicryl-1 sutures. The peritoneal
cavity will be rinsed and haemostasis checked. No drains
will be left in the peritoneal cavity unless indicated (dif-
ficult haemostasis). The 5 mm trocars will be removed
under direct vision. The 10 mm trocar will be removed.
The fascial layer will not be sutured. The umbilicus and
other incisions will be disinfected with iso-Betadine
solution. The skin incisions will be closed using a
monocryl 3/0 intradermal suture and steristrips. The
wound sites will be covered with a standard bandage.
A vaginal pack (Betadine gauze 10 cm×5 m) will be
placed to be removed 3 hours later together with the
Foley catheter.
Intervention group: NOTES
When randomised to the NOTES approach, three non-
therapeutic superficial skin incisions will be made on
the same location as in the classical laparoscopic
approach. The surgeon will assess whether the anterior
and posterior colpotomy and the transsection of both
sacrouterine ligaments are best performed with either
laparoscopic instruments (total vaginal NOTES hysterec-
tomy, TVNH), or with classical instruments for vaginal
surgery (vaginally assisted NOTES hysterectomy, VANH).
For VANH
A circular incision will be made around the cervix using
a cold knife. The Pouch of Douglas will be opened
using a cold scissors. The vesicouterine peritoneum will
be opened using a cold scissors. Both sacrouterine liga-
ments will be cut using a cold scissors and tied off using
a vicryl-1 suture. A GelPOINT Advanced Access Platform
(Applied Medical) will be used as the vNOTES port and
inserted into the peritoneal cavity. CO2 will be insuf-
flated until a maximal intraperitoneal pressure of
15 mm Hg. An optic fibre will be inserted and the peri-
toneal cavity inspected. The patient will be placed in the
Trendelenburg position. The small intestine will be
lifted out of the pelvis.
For TVNH
GelPOINT Mini Advanced Access Platform (Applied
Medical) will be used as the NOTES port and inserted
into the vagina. CO2 will be insufflated until a maximal
pressure of 15 mm Hg. An optic fibre will be introduced
into the pneumovagina. A circular incision will be made
around the cervix using a monopolar laparoscopic
hook. The Pouch of Douglas will be opened using a
cold laparoscopic scissors. The vesicouterine peritoneum
will be opened using a cold laparoscopic scissors. Both
sacrouterine ligaments will be cut using a laparoscopic
bipolar grasping forceps. An optic fibre will be inserted
and the peritoneal cavity inspected. The patient will be
placed in the Trendelenburg position. The small intes-
tine will be lifted out of the pelvis.
The following steps of the procedure are identical for
VANH and TVNH:
The ureter will be identified, but not routinely dis-
sected unless indicated. The uterine and ovarian arteries
will be coagulated using a bipolar grasper and cut. The
mesosalpinx will be coagulated and cut using a bipolar
grasping forceps and a scissors. In women requiring
adnexectomy, the infundibulopelvic ligament will be
coagulated using a bipolar grasping forceps and cut.
Haemostasis will be checked and the peritoneal cavity
will be rinsed. The NOTES port and the uterus will be
removed through the vagina and the pneumoperito-
neum will be deflated. The colpotomy will be closed
using a running vicryl-1 suture. A vaginal pack (Betadine
gauze 10 cm×5 m) will be placed and removed after
3 hours together with the Foley catheter.
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Occasionally, the surgical removal of a benign diseased
uterus by any of the two techniques may not be com-
pleted according to the random sequence generation
because of technical limitations or unexpected findings
such as extensive adhesions or unexpected malignancy.
Successful NOTES or laparoscopic hysterectomy is feas-
ible in the majority of women, but the probability of
success is not readily predictable. In cases where the
intended procedure has to be abandoned, the appropri-
ate technique (eg, staging laparotomy for ovarian
cancer) or a second procedure (eg, laparoscopy or
laparotomy after bowel preparation) under general
anaesthesia should be scheduled as soon as possible.
Women who require an alternative more appropriate
intervention or a second procedure are not excluded or
withdrawn from the HALON trial. The investigators will
sensitively explain to them that follow-up information is
still very important, despite the change in treatment,
and unless they wish to withdraw completely from the
trial, they will be followed up.
It is anticipated that most women presenting with a
suspected benign diseased uterus will require no further
intervention other than removal of the uterus with or
without the adnexa. However, in some circumstances
additional medical treatments may be considered neces-
sary by the responsible clinician at the time of surgery
or subsequently. This will be recorded. However, if the
need for additional surgery at the time of surgery is indi-
cated, then such patients will be excluded for recruit-
ment to the HALON trial. All therapeutic interventions
in addition to the removal of the uterus with one or
both adnexa will be recorded and as the trial is rando-
mised we anticipate that these further interventions will
be symmetrically applicable.
The pain management for both groups will be identi-
cal using a standardised protocol developed by the
anaesthesiologists involved in the clinical trial. The pain
protocol and a printed copy of the study protocol of the
HALON trial will be available for consultation in the day
care unit, the operating theatre and the recovery room.
All steps of the intervention will be discussed with the
team during the time-out and specific instruction about
analgesics according to the protocol, the time to remove
the bladder catheter and the vaginal pack will be noted
before sign-out by the anaesthesiologist and the
surgeon. The care given by the nurses at the day care
unit will be extensively described by a dedicated nurse at
the day care unit as a guideline for treating participants
in a standardised way.
The decision to discharge the study participant from
the day care unit or alternatively to admit her to the
in-hospital ward will be primarily decided by the patient
based on how she feels following surgery. Both the
patient and the outcome assessor (JJAB), who will super-
vise the discharge, will be blinded to the approach used
for the hysterectomy. The outcome assessor will overrule
the participant’s decision only in her health’s interest for
example, when vital parameters indicate a life-threatening
condition or based on the presence of complications
during the surgical intervention as indicated in the
patient record. All study participants will receive a stand-
ard list including instructions to avoid sexual intercourse
and physical exercise/work for a period of 6 weeks after
hysterectomy.
All women will be asked to measure postoperative
pain using a Visual Analogue Scale (VAS) twice daily
from day 1 to day 7 following surgery, regardless of
being at home or in hospital. A dedicated nurse of the
day care unit will give detailed instructions to all partici-
pants on how to measure the VAS scores. One measure-
ment will be done in the morning after bed rest at night
(rest) and the other will be done in the evening before
going to bed after physical activity (active). All study par-
ticipants will note in a pain log book the name, dosage
and route of administration of any analgesic drug taken
from day 1 to 7.
Outcome measure
We searched the COMET17 database for a core outcome
set for surgery (intervention) in gynaecology (health
area) in women aged 18–70 years (target population):
we did not retrieve a standardised set of outcomes rele-
vant to laparoscopic hysterectomy.18
Primary outcome measure
The proportion of women successfully treated by remov-
ing the uterus by the intended approach without conver-
sion to another approach will be used as a measure of
efficacy.
Secondary outcome measures
The secondary outcomes are as follows: (1) the propor-
tion of women admitted to the in-hospital ward for at
least one night observation. Women can decide for
themselves whether to leave the day care unit or stay
overnight based on how they feel after the surgical pro-
cedure. The goal is to recover at home with their family
for a fixed period of 6 weeks. The aim of this study was
not to examine if participants were able to re-engage in
their professional activities sooner with NOTES com-
pared with laparoscopy; (2) postoperative pain scores
measured using a VAS19 twice daily from day 1 to 7; (3)
the use of analgesics taken during the first week follow-
ing surgery; (4) postoperative infection defined by lower
abdominal pain with fever >38°C and positive clinical
signs or laboratory findings detected during the first
6 weeks of surgery; (5) intraoperative or postoperative
complications according to the Clavien-Dindo classifica-
tion20 detected during the first 6 weeks of surgery; (6)
readmission during the first 6 weeks of surgery; (7) fre-
quency and intensity of dyspareunia recorded by the
participants at baseline, 3 and 6 months by self-reporting
using a simple questionnaire and VAS; (8) sexual well-
being at baseline, at 3 and 6 months by self-reporting
the Short Sexual Functioning Scale (SSFS). The ‘SSFS’
is a self-developed questionnaire consisting of four items
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that address sexual dysfunctions: decreased sexual
desire, dry vagina, orgasmic dysfunction and dyspar-
eunia. Each of these items are scored on a four-point
scale ranging from 0 (not or doubtfully present) to 3
(extremely present). Reliability analysis of the SSFS
revealed an excellent internal consistency (Cronbach’s α
0.92) in two prospective controlled studies on sexual
functioning after mastectomy compared with breast-
conserving therapy for early-stage breast cancer21 and
after surgical treatment of vulvar malignancy.22 The
SSFS has been used as a research tool in several other
publications;23–25 (9) the duration of surgery measured
in minutes from the insertion of the bladder catheter to
the end of vaginal/abdominal wound closure and (10)
direct and indirect costs for both techniques incurred
up to 6 weeks following surgery.
Recruitment
All women aged 18–70 years, regardless of parity, with a
non-prolapsed uterus in need of a hysterectomy for
benign indications are eligible for inclusion. We will
introduce the trial to all eligible women in the out-
patient clinic. A comprehensive, evidence-based patient
information sheet will be provided at the clinic visit.
Participant information sheets and consent form will be
provided in Dutch.
Before the procedure, the women will be given a
chance to discuss the risks and benefits of NOTES or
laparoscopy for removing the uterus, the process of ran-
domisation and the follow-up requirements with the
consultant gynaecologist. It will be carefully explained
that the final decision about eligibility will be taken
during the surgical procedure and is dependent on the
findings; therefore consent will be required before the
procedure, in every instance.
Over the past 3 years 504 hysterectomies were per-
formed at the department of obstetrics and gynaecology
of the participating centre. The mean number of proce-
dures per year is 168 (±SD 19). About 40% of the eli-
gible women should be willing to participate in the
proposed study to recruit the required amount of parti-
cipants within 1 year.
Randomisation and blinding
After stratification according to the uterine size on clin-
ical examination, all participants will be randomly
assigned to either the intervention (NOTES) or the
control group (laparoscopic technique) using a
computer-generated randomisation schedule after strati-
fying for the size of the uterus. The study secretary will
generate the allocation sequence and assign the partici-
pants to one of both interventions. Sequentially num-
bered, opaque, sealed envelopes will be used to ensure
allocation concealment.
Trial participants, personnel and the outcome assessor
will be blinded to group allocation.
The use of the NOTES technique avoids the use of
abdominal incisions. Participants randomised to the
intervention group will have three superficial non-
therapeutic skin incisions similar to those routinely
done with the laparoscopic technique to blind all study
participants, personnel and the outcome assessor.
Wound dressings of all the study participants will be left
untouched until the postoperative visit on day 7. The
practice of performing non-therapeutic skin incisions
has been reported in some surgical trials to minimise
performance and detection bias when measuring sub-
jective outcomes (eg, pain).26 The decision to use non-
therapeutic skin incisions is justified by the risk/benefit
ratio of the two interventions under comparison.27
To ensure blinding in case of a suspected adverse
event, the outcome assessor will notify the surgeon to
assess if a surgical intervention is needed. The partici-
pant’s allocated intervention will be revealed by the
study secretary when the last questionnaires at 6 months
have been sent to the Trial office.
Data collection and management
All baseline outcomes and other trial data will be col-
lected paper-based by the outcome assessor, who has
been trained and certified in Good Clinical Practice
(GCP). We will use the following instruments: VAS for
measuring postoperative pain and dyspareunia, the SSFS
for measuring sexual well-being with an excellent
internal consistency (Cronbach’s α 0.92) in two prospect-
ive studies21 22 and the EQ-5D (Euro Qol descriptive
system of health-related quality of life states consisting of
five dimensions) which is a widely used and validated tool
for measuring health-related quality of life.
We will promote participant retention and complete
follow-up by scheduling a first visit 1 week after surgery
for collecting pain scores and data on the use of analge-
sics and a second visit after 6 weeks to collect data on
postoperative complications. The study secretary will
send reminders to study participants if needed to send
the questionnaires at 3 and 6 months. We will collect
data on the successful removal of the uterus and admis-
sion to the in-hospital ward of women who discontinue
prematurely after having been randomised. Women who
do not adhere to the follow-up schedule will be con-
tacted by the outcome assessor and will be given an
appointment for assessment as soon as possible. We will
record the reasons for non-adherence and non-retention
because this information can influence the handling of
missing data and the interpretation of the study results.
To reduce loss to follow-up, we shall record patient’s
social security number, which allows us to track patients
changing GP practice. With postal and telephone remin-
ders we anticipate that, the completeness of data should
surpass 90% although, as set out below incomplete
follow-up is incorporated into the power calculations.
Owing to the time and costs associated with double
data entry, we will use single data entry from the
patient’s electronic file into paper clinical research
forms. This ensures a centralised approach to monitor-
ing data quality and compliance. A computer database
Baekelandt J, et al. BMJ Open 2016;6:e011546. doi:10.1136/bmjopen-2016-011546 5
Open Access
copyright.
 o
n
 July 27, 2020 at University of Aberdeen. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-011546 on 12 August 2016. Downloaded from 
will be constructed specifically for the study data and
will include range and logic checks to prevent erroneous
data entry. Independent checking of data entry of paper
questionnaires will be periodically undertaken on small
subsamples by the study secretary. The trial statistician
will regularly check the balance of allocations by the
stratification variables. Source data verification will only
be employed if there is reason to believe that data
quality has been compromised.
Statistical methods
Sample size calculation
A sample size calculation was performed for the primary
outcome: an appropriate level of statistical power was
applied to preclude any clinically important inferiority
of NOTES compared with laparoscopy. The assumptions
for the conversion rates are based on evidence retrieved
from a Dutch prospective cohort study in 42 hospitals
including 1534 laparoscopic hysterectomies between
2008 and 2010:28 this study reports a 4.6% conversion
rate. We assume that NOTES would be the treatment of
choice for the majority of women primarily related to
the cosmetic results (no abdominal scars) even if 15%
less women had successful removal of their uterus with
NOTES compared with the laparoscopic approach. We
will conclude non-inferiority when 15% lies above the
upper limit of the 95% CI calculated for the difference
in the proportion of women successfully treated with
either of the two techniques. To achieve 80% power to
demonstrate non-inferiority under the assumption of
similar success rates of 95% in both groups a sample size
of 54 participants (27 women per group) will be
required. The target sample size was increased to 64 par-
ticipants (32 women per group) to account for a
drop-out rate of 15%.
We aim to report the actual conversion rates at the
end of the study. We predefine that the trial validity is
not compromised if the conversion rates are below 10%
and similar in both comparison groups. The study
design (non-inferiority) is based on the assumption that
the conversion rates are similar in both comparison
groups, which will be cross-checked at the end of the
study.
Statistical analyses
A 95% CI of the difference in the proportions of
women with a successful removal of the uterus by the
intended technique as randomised will be calculated.
Non-inferiority will be concluded when 15% lies above
the upper limit of this 95% CI. For this primary analysis,
adjustments for prognostic factors will not be made in
the first instance. Body mass index (BMI) >35 kg/m2,
age >65 years, uterine weight 200–500 g or uterine
weight >500 g have been identified as prognostic factors
for the risk of conversion based on the findings of the
earlier cited Dutch prospective cohort study:28 the risk
of conversion was increased at BMI>35 kg/m2 (OR 6.53;
p<0.001), age >65 years (OR 6.97; p=0.007), uterine
weight 200–500 g (OR 4.05; p<0.001) and uterine weight
>500 g (OR 30.90; p<0.001). The effect of BMI and age
will be explored as a secondary analysis. We aimed to
include women without genital prolapse in the HALON
trial because we do not consider the NOTES technique
to be an alternative for vaginal hysterectomy in women
with genital prolapse. Nulliparous women with a narrow
vagina could certainly represent an impediment when
performing the NOTES technique. In practice NOTES
can be done using a VANH or a TVNH approach. The
VANH approach is used when the vaginal vault can be
reached to open the Pouch of Douglas in a comfortable
way. In nulliparous women with a narrow vagina we will
use another approach: with the TVNH approach the
cervix is circumcised using a monopolar hook and the
pouch is opened using laparoscopic scissors. The pres-
ence or absence of enough prolapse of the vaginal vault
could affect the conversion rates. We will explore this
effect in a secondary analysis but we will be very cautious
in presenting definitive conclusions for this predefined
subgroup analysis: given the limited number of included
participants, it is likely that differences even when really
present, will fail to reach statistical significance.
Multilevel modelling for repeated measurements will
be used to compare the mean differences in VAS pain
scores between both comparison groups over all time
points, thereby maximising the power of the data avail-
able. VAS scores will be transformed if required to meet
model assumptions.
Analysis will be performed on an ‘intention-to-treat’
basis in the first instance, as recommended in the
Consolidated Standards of Reporting Trials (CONSORT)
statement.29 A sensitivity analysis will be performed using
‘per protocol’ data to test the robustness of findings. As a
conservative measure, estimates of effect sizes between
the two arms will be presented as point estimates with
two-tailed 95% CIs.
Descriptive statistics will be used to summarise
patients’ characteristics and baseline outcome data in
the two treatment groups. Baseline characteristics of the
women enrolled in the two groups will be compared to
ensure that the randomisation has produced compar-
able groups of participants, and will be covariates in the
modelling procedure.
The statistical significance test for the primary analysis
will be one-tailed, and p<0.05 will be considered as sig-
nificant. All tests of the secondary analyses will be two-
tailed, and p<0.05 will be considered as significant. All
statistical analyses will be performed by an experienced
biostatistician (AL) who is also a co-investigator in the
present research.
The interpretation of missing values in the analysis of
clinical trials can be fraught with danger. The methods
used to allow for missing data make assumptions about
the reasons for data not being present, such as in the
‘observed case’ analysis, where the presence or absence
of data is viewed as unrelated to outcome, or in the ‘last
observation carried forward’ analysis where the
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assumption is that the condition does not improve or
worsen following withdrawal from follow-up. To minim-
ise possible biases, participants will continue to be fol-
lowed up even after protocol treatment violation.
Missing data items will be imputed from given values if
limited to a single-item response. If a form is missing
entirely or is greater than one item imputation will not
be attempted. Sensitivity analyses will be carried out to
determine whether or not the results obtained are
robust to the methods used to handle missing data.
Questionnaires will only be treated as late if they are
returned after the subsequent questionnaire has been
sent to the patient. However, if this form is the only
form available at the later time point it will be included
at the subsequent time.
Monitoring
HALON is a trial of short duration. Therefore, a data
monitoring committee is not needed.
All adverse events reported spontaneously by the par-
ticipant or observed by the investigator or his staff will
be recorded. Infection and peroperative or postoperative
complications will be assessed as secondary outcomes
until 6 weeks after surgery. We will inform the family
physician of all participants in order to assess all possible
unintended effects of the trial intervention and promote
to report all possible adverse events anonymously using
the participant’s unique study number to an email
address (NOTES@imelda.be). We will use descriptive sta-
tistics for data analysis although the trial is not
adequately powered to detect important differences in
rates of uncommon adverse events. Given the limited
resources and the single-centre design there will be no
auditing of the conduct of the trial. We will review
patient enrolment, consent and eligibility on a regular
basis to promote data quality and to preserve trial integ-
rity. The distribution of the allocation to the study
groups will be blindly checked by the study secretary at
30%, 60% and 90% of the recruitment and discussed
with the study statistician and the principal investigators.
RESULTS
Participant flow diagram
We will shows the study flow reported according to the
CONSORT statement and checklist in the final report of
the HALON trial.29
Recruitment time frame
All women with a non-prolapsed uterus, aged 18–
70 years, regardless of parity, in need of a hysterectomy
for benign indication and meeting the inclusion criteria
will be invited to participate in the trial. Only eligible
women with written informed consent obtained before
randomisation will be included in the trial.
On the basis of the mean number of hysterectomies
performed for benign gynaecological disease in women
without genital prolapse at the department of
gynaecology annually (N=168) we estimate that 40% of
the eligible women should be willing to participate in
the recruit sample size needed (N=64) within 1 year.
Based on the follow-up (6 months) and the period of
analysis/reporting (6 months) the total study period is
estimated to be 2 years.
Data collection
The following patient characteristics will be recorded at
baseline: age, BMI, volume of the uterus in weeks, con-
comitant medication, dyspareunia questionnaire, the
SSFS and the EQ-5D questionnaire.
On the day of surgical intervention (day 0) the follow-
ing data will be collected: duration of the intervention,
successful removal of the uterus by the technique as ran-
domised without conversion to another technique with
or without cleaving the uterus, admission of the partici-
pant to the in-hospital ward for at least one night obser-
vation based on her own preference, the total amount of
analgesics used at the recovery and day care unit and
the maximum VAS pain score on the day 0.
On days 1–7 the pain scores will be collected as
reported by the study participant twice daily (1 in the
morning and 1 in the evening). The total amount of
analgesics used during the first postoperative week will
be recorded by the participants and collected by the
outcome assessor.
On days 7 and 42 pelvic infection defined by lower
abdominal pain with fever >38°C and positive clinical
signs or laboratory findings, concomitant medication,
readmission and postoperative complications according
to the Clavien-Dindo classification detected during the
first 6 weeks after the intervention will be assessed and
recorded by the outcome assessor.
On months 3 and 6 following surgery the dyspareunia
questionnaires, the SSFS questionnaires and the EQ-5D
questionnaires will be filled out by the study participants
and collected (table 1).
DISCUSSION
Strengths and weaknesses
The main strength of the HALON study is its design as a
RCT rather than an observational comparative study.
A RCT has the advantage to control for all possible
known and unknown confounding variables due to the
random sequence generation as opposed to observa-
tional studies where confounding and bias may be more
problematic. High-quality RCTs are generally considered
as being the gold standard for studying the effectiveness
of an intervention.
Restricting this single-centre RCT to one surgeon’s
practice may be considered a major limitation. We never-
theless have carefully balanced the pros and cons of this
decision. There can be no discussion on the learning
curves or differences in surgical skills among the partici-
pating surgeons if all study participants are treated
by one surgeon equally skilled at performing both
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techniques. A multicentre prospective cohort study
could add credibility to the generalisability of the find-
ings, but may pose problems with respect to the learning
curves and the differences in surgical skills of the sur-
geons involved. The aim of the present pilot study is to
study the efficacy (Can NOTES work under ideal experi-
mental conditions?). The HALON trial does not address
the effectiveness of the new intervention (Does NOTES
work in a real-life setting when performed by several
surgeons?). Multicentre trials on the effectiveness of
NOTES should be carried out when there is evidence
of efficacy and after proper training of a larger group
of dedicated surgeons as suggested by the IDEAL
recommendations.
The conditions in this small efficacy study are experi-
mental and in many instances opposed to ‘real-life’ con-
ditions: all women are treated by one surgeon equally
skilled in using both techniques, women are given better
care in this study when compared with standard clinical
practice, the dosage of anaesthetic drugs is calculated to
limit the possible side effects such as nausea and vomit-
ing that may prevent women leaving the hospital the
same day, all outcomes measured are very relevant for
women in general, women with adverse outcomes (eg,
dyspareunia and sexual dysfunction) will be recalled
after the end of the study for counselling and therapy,
etc. The results of the HALON trial will therefore have a
limited generalisability and their interpretation will be
carried out cautiously.
By making three ‘non-therapeutic incisions’ on the
abdomen in the NOTES group it could be argued that
this intervention may confound the assessment of the
pain outcome. We judged it necessary to blind partici-
pants, personnel and the outcome assessor by using
these ‘non-therapeutic incisions’ similar to the ones
used in the laparoscopic technique. If we would have
stuck to the pure NOTES technique without scars on
the abdominal wall, participants in the intervention arm
(NOTES) would have known with certainty that they
had undergone the ‘new promising technique’: this
could have introduced substantial bias and would have
compromised the internal validity of the HALON trial.
After carefully balancing the pros and cons, all the inves-
tigators agreed to sacrifice a potential benefit of the
NOTES technique (less pain and better cosmetic results
by not using abdominal incisions) rather than comprom-
ising the study validity by introducing information bias.
We accept a possible decrease in the magnitude of a
potential benefit and we will report this balanced judge-
ment in the final review.
We considered stratifying for other determinants than
the uterine size (BMI and parity) but given the scope
and the limitations of this small pilot RCT study we
decided to stratify only for the uterine size on clinical
examination.
Many outcomes of the present study are patient-
reported and patient-centred. The secondary outcome
‘the proportion of women admitted to the in-hospital
ward for at least one night observation’ could equally
confound the study results if there would be different
and substantial proportions of women wishing to stay for
reasons not related to the surgery itself (eg, social
reasons) across both comparison groups. Women in the
HALON trial can decide for themselves to leave the day
care unit or stay overnight based on how they feel after
the surgical procedure. The goal is to recover at home
with their family for a fixed period of 6 weeks. The aim
of this study was not to examine if participants were able
to re-engage in their professional activities sooner with
NOTES compared with laparoscopy. We admit that the
reasons to stay overnight are not necessarily medical. In
cases where the reasons to stay overnight was not purely
Table 1 Patient’s characteristics and data collection
Data collection
Days
BL 0 1 2 3 4 5 6 7 42 3 months 6 months
Age X
BMI X
Uterine volume X
Concomitant medication X X X X X X X X X X
Dyspareunia: frequency and intensity X X X
SSFS X X X
Health-related quality of life X X X
Duration of surgery X
Successful removal X
Admission in hospital (for at least 1 night) X
Total amount of analgesics used X X X X X X X X
VAS score X X X X X X X X
Readmission within 6 weeks X
Pelvic infection X X
Other postoperative complications X X X
Direct and indirect costs (up to 6 weeks after surgery) X
BL, baseline; BMI, body mass index; SSFS, Short Sexual Functioning Scale; VAS, Visual Analogue Scale.
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medical and as such reported by the participant, we
noted this as an additional remark in the clinical
research file. The primary analysis will be made based
on the fact of staying overnight or leaving the day care
unit without taking into account the nature of the
reasons for staying. We assume that by using the random
sequence generation women wishing to stay overnight
for social reasons should be equally distributed among
both comparison groups. This will be cross-checked if all
study data are available. We will do sensitivity analyses if
differences are found across the comparison groups for
the reasons reported by participants for staying over-
night to test the robustness of the data.
Implications for clinical practice
We stress that the HALON trial is a pilot study on the effi-
cacy of the NOTES technique. The two techniques
under comparison are performed by one single surgeon
( JB) who is equally skilled in using both techniques. The
surgeon has been using the new approach since
November 2013. During this 2-year period the new tech-
nique and suitable instruments used were pilot-tested by
the usual ‘trial and error’ method used for centuries in
surgical practice13 and adapted into its present form.
The feasibility and preliminary safety of the new tech-
nique was reported in three observational studies per-
formed in our department14–16 in accordance with the
principles outlined in the three article series on the
IDEAL statement.11–13 According to the terminology
used by the IDEAL collaboration13 this study should be
classified as an IDEAL stage 2b trial. The full Patient-
Intervention-Comparison-Outcome (PICO) research
question is as follows: will a surgeon who is equally skilled
at performing both techniques, and beyond his learning
curve for the new technique (NOTES), succeed in
removing a non-prolapsed uterus in women with benign
gynaecological disease at least as often with the new pilot-
tested vNOTES approach compared with the standard
transabdominal laparoscopic approach without having
to convert to an alternative approach? The findings of
the HALON study have limited generalisability. Adequate
training of other surgeons and more research for
example, prospective multicentre prospective cohort
studies or large electronic registries will be needed to
monitor the long-term outcomes (eg, surgical complica-
tions). The reader should be aware that a proof of effi-
cacy by a single-centre pilot study is by itself not sufficient
to implement the technique into clinical practice.
We do not consider the NOTES approach as being a
more suitable alternative for the vaginal hysterectomy in
cases of genital prolapse. The aim of the HALON study
is to compare NOTES with laparoscopic hysterectomy in
women with non-prolapsed uterus for benign gynaeco-
logical pathology. Although NOTES could have been
compared with classical vaginal hysterectomy and one
might be tempted to consider vaginal hysterectomy as a
NOTES technique, our goal was to remove uteri that in
a setting outside of the trial would have been removed
by a total laparoscopic approach or open abdominal
approach, that is, without sufficient prolapse to do a
classical vaginal hysterectomy. The NOTES technique
moreover uses a device to create and maintain a pneu-
moperitoneum in contrast to a vaginal hysterectomy. We
hypothesise that gynaecologists will feel more familiar
with using NOTES for removing a non-prolapsed uterus
compared with performing a total laparoscopic
approach: NOTES avoids suturing laparoscopically
which requires considerable skill. If the uterus is bulky,
the NOTES approach will enable the surgeon more
direct access to the uterine blood supply as opposed to
the laparoscopic approach. Trying to coagulate the
uterine vessels in a bulky uterus filling the pelvic cavity
can be quite challenging.
Implications for further research
As suggested by the IDEAL collaboration more research
(large multicentre trials performed by adequately
trained surgeons in centres of clinical excellence and
large prospective registries cumulating data on the safety
of the new technique over many years) and adequate
surgical training will be needed before NOTES can be
offered as a standard daily care surgical practice by a
majority of gynaecological surgeons for all women
bound to undergo hysterectomy for benign gynaeco-
logical disease. HALON should therefore be considered
as a necessary kick-off in a long and scientifically rigor-
ous evaluation of a complex surgical intervention. A ran-
domised pilot study on the efficacy of NOTES is needed
at this moment in its evolution before this technique
becomes widely implemented into daily clinical practice
without properly evaluating its potential benefits and
harms: the latter scenario is not in accordance with GCP
and may harm women in the longer term.
ETHICS AND DISSEMINATION
The HALON trial will be conducted in accordance with
the ethical principles set out in the latest version of the
‘Helsinki Declaration’, the ‘Guideline for Good Clinical
Practice’ and the Belgian Law of 7 May 2004 related to
experiments on humans.
A detailed patient information document about the
study protocol, the aims of the research and the possible
adverse events related to the surgical techniques under
comparison will be provided to all eligible women
wishing to participate in the trial. We will request written
informed consent from all participants before random-
isation. This will be obtained by the principal investiga-
tor ( JB) and the coordinating investigator (JJAB) during
a study intake. An adapted informed consent form was
drafted based on the template proposed by the Federal
Agency for Medicines and Health Products (FAMHP)
for clinical research in Belgium.30
The protocol of the HALON trial is registered in
ClinicalTrials.gov of the US National Institutes of Health
as NCT02631837 (see online supplementary appendix 1
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—items WHO Trial Registration Data Set). The study
protocol and the informed consent documents (see
online supplementary appendix 2—model consent form
in Dutch) have been approved by the Ethics Committee
of the Imelda Hospital Bonheiden (registration number
689), Belgium on 1 December 2015. The written
approval with the Belgian unique study identifier
B689201526261 was sent to the FAMHP in Brussels. We
will communicate important protocol modifications to
the Ethics Committee of the Imelda Hospital, the
FAMHP, all trial participants and ClinicalTrials.gov.
The HALON trial is non-commercial and investigator
driven. The investigators have taken out an insurance
policy for medicolegal responsibility related to the
conduct of the study from 1 December 2015 to 30
November 2017 in accordance with Article 29 of the
Belgian Law of 7 May 2004 related to experiments on
humans.
The clinical research forms and all other study-
related documents will be stored securely at the study
site in locked file cabinets in an area with limited
access. All records that contain names or other per-
sonal identifiers will be stored separately from study
records identified by a code number. Data collection,
storage and dissemination will be in accordance with
the Belgian Law of 8 December 1992 on the protec-
tion of privacy in relation to the processing of per-
sonal data and by the Law of 22 August 2002 on
patient rights.
All nine trial investigators (all authors of the protocol
of the study) will be given access to the complete final
data set at the end of the HALON study.
Offering surgical intervention identified as being most
effective or most advantageous after the final analysis of
the study data to those women allocated to the other
comparison arm is by the nature of the surgical inter-
vention impossible. We will provide post-trial care to
those women with identified adverse outcomes in the
longer term (dyspareunia or sexual dysfunction) as part
of good clinical research practice.
The trial results will be disseminated through scientific
journal manuscripts and scientific conference presenta-
tions. All investigators will contribute to authorship. We
will follow the authorship eligibility guidelines of the
International Committee of Medical Journal Editors
(ICMJE).
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